Zoetis Inc. ZTS
Composite 56/100; the shares have moved about 44% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 20/100 — a strong mark against it.
Quality ranks 79/100 — a strong point in its favour. Income ranks 73/100 — a moderate point in its favour. Valuation ranks 60/100 — a slight point in its favour.
Momentum ranks 20/100 — a strong mark against it. Growth ranks 48/100 — a slight mark against it.
What the company does Zoetis Inc. (ZTS) discovers, develops, manufactures and commercializes medicines, vaccines, diagnostics and precision animal health solutions for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). Its portfolio spans parasiticides, vaccines, dermatology, anti-infectives, pain/sedation products, diagnostics and biodevices.
Key financials ZTS reports ROE 64.9%, ROA 15.3%, gross margin 71.7%, operating margin 40.7% and net margin 27.7%. Revenue grew 2.3% and EPS grew 9.8%. Dividend yield is 2.7% with a 31.8% payout ratio. Forward P/E is 12.11 and EV/EBITDA is 9.60.
Stock health SiderAvia scores Quality 79.3 and Income 69.8 but Momentum only 19.0. The stock is down -49.27% over 12 months and -49.63% from its 52-week high; RSI(14) is 53.40.
Price vs fair value The stock trades at a discount of 24.10% versus the analyst mean target of 96.00. - Phibro Animal Health’s Q4 call highlighted competitive animal-health dynamics (2026-08-27). - Forward PEG of 11.21 signals valuation headroom relative to growth. - SiderAvia Valuation percentile 55.8/100 indicates moderate attractiveness.
Looking forward Analysts expect forward P/E 12.11 and net margins near 28%, supported by steady companion and livestock demand. Pipeline collaboration with Blacksmith Medicines targets novel antibiotics, a potential long-term catalyst.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.